Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results
Date:2/24/2011

building our European organization, increased marketing expenses, legal costs and compensation expense partly offset by decreased medical education expenses.

Our income tax expense was $75.3 million and $41.0 million for the year ended December 31, 2010 and 2009, respectively.  The effective tax rate in 2010 was 37.5 percent compared to 137.0 percent in 2009.  The effective tax rate in 2010 exceeded the federal statutory tax rate due to state income taxes and certain share-based compensation that is not tax deductible.  The effective tax rate in 2009 exceeded the statutory tax rate because of a goodwill impairment charge which was not deductible for tax purposes and state income taxes, partially offset by an orphan drug credit.

Working Capital HighlightsAt December 31, 2010, our working capital was $561.0 million compared to $406.4 million at the end of 2009 as we generated $193.5 million in cash flow from operations during 2010.

Looking ahead in 2011ViroPharma is reiterating its guidance for the year 2011 as a convenience to investors.  The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties.  For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2011, ViroPharma expects the following:

  • Net Cinryze sales are expected to be $235 to $260 million.

  • Research and development (R&D) and selling, general and administrative (SG&A) expenses are expected to be $170 to $190 million.  

  • Conference Call and WebcastViroPharma is hosting a live teleconference and webcast with senior management to discuss the financial announcement, guidance, and other business results on February 24, 2011 at 9:00 a.m. Eastern. To participate in the conference ca
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. ViroPharma to Present at Three September Healthcare Conferences
    2. ViroPharma to Present at Three October Healthcare Conferences
    3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
    4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
    5. ViroPharma to Present at Three November Healthcare Conferences
    6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
    7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
    8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
    9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
    10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
    11. ViroPharma to Present at Two June Healthcare Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/26/2015)... Los Angeles, CA (PRWEB) February 26, 2015 ... organizing an online demonstration to support life extension technologies ... to 8pm UTC, Universal Coordinated Time, on March 21st ... around the world. , Eric Schulke, Founder of ... we must act with urgency. The Movement for Indefinite ...
    (Date:2/26/2015)... BioEnterprise today announced that Northeast Ohio ... in growth funding during the past 13 years.  Funding ... – including the Ohio Third Frontier - and federal ... raised in the past five years. ... BioEnterprise Midwest Healthcare Growth Capital  Report.   ...
    (Date:2/26/2015)... February 26, 2015 RURO, Inc., a ... FreezerPro® version 6.2 – the latest update to the ... is that of a quick and easy method to ... the latest version, RURO engineering has enhanced the system’s ... move large amounts of sample records. , "FreezerPro ...
    (Date:2/26/2015)... Calif. , Feb. 26, 2015 ... Gold Partner status in Oracle PartnerNetwork. In attaining Gold ... its commitment to establish Oracle-related knowledge in delivering Ceres, ... challenges of joint customers. Originally developed for ... to rapidly zoom in and out of massive amounts ...
    Breaking Biology Technology:Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4RURO Releases FreezerPro® version 6.2 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4
    ... Oct. 25 Cellectis (Alternext: ALCLS), the French genome ... and Application (CiRA) of Kyoto University, Kyoto, Japan, have ... to combine Cellectis, genome engineering technologies with CiRA,s induced ... characteristics of iPS cells for use as cellular tools. ...
    ... Oct. 22 Trius Therapeutics, Inc. (Nasdaq: TSRX ... at Trius Therapeutics, will present "Innovative Antibacterial Drugs by Design; ... event taking place on October 26, 2010 from 5:30-9:30 p.m. ... available at http://sdbn.org/october . About ...
    ... Bacterin International Holdings, Inc. (OTC Bulletin Board: ... for medical applications and revolutionary bone graft material, today ... M. Wickwire, a distinguished Washington, D.C. based attorney and ... & Carparelli, to its Board of Directors.  Effective immediately, ...
    Cached Biology Technology:Cellectis and the Center for iPS Cells Research and Application Enter Collaboration 2Cellectis and the Center for iPS Cells Research and Application Enter Collaboration 3Bacterin International Reconstitutes Its Board of Directors and Appoints Experienced Legal and Financial Professionals 2Bacterin International Reconstitutes Its Board of Directors and Appoints Experienced Legal and Financial Professionals 3Bacterin International Reconstitutes Its Board of Directors and Appoints Experienced Legal and Financial Professionals 4
    (Date:2/18/2015)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. , Cowen and ... Tuesday, March 3, 2015 at 11.20 a.m. Eastern Time ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern ... webcasts for these events, please visit Cepheid,s website at ...
    (Date:2/12/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... for DISTRIBUTED METHOD AND SYSTEM TO IMPROVE ... further establishes NXT-ID,s position in the emerging "Internet of ... ability for multiple devices to collaborate with one another ...
    (Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
    Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
    ... Planck Institute for Human Cognitive and Brain Sciences and ... now developed a mathematical model which could significantly improve ... the future, this kind of algorithms which imitate brain ... them. Many people will have personal experience of ...
    ... cells for replication and production of virus progeny. Thus ... induces therapy resistance. New improved therapies attempt to targets ... The team led by Professor Dr. Ralf Bartenschlager, ... Hygiene Institute of Heidelberg University Hospital, has identified a ...
    ... at Carnegie Mellon University have developed an analytical technique ... complex disease syndromes such as diabetes, asthma and cancer, ... , Rather than searching one at a time for ... as in most conventional approaches, the Carnegie Mellon ...
    Cached Biology News:Doing what the brain does -- how computers learn to listen 2Doing what the brain does -- how computers learn to listen 3New strategy for inhibiting virus replication 2Carnegie Mellon develops innovative method to detect genetic causes of complex diseases 2
    ... utilize the membrane-permeant ester forms (CCF2-AM ... fluorescent beta-lactamase substrates, CCF2 and CCF4. ... cell, where cleavage by endogeneous cytoplasmic ... negatively charged forms, thereby trapping them ...
    ...
    Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
    ...
    Biology Products: